FDA Approves Repatha (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia

By | September 28, 2021

[unable to retrieve full-text content]THOUSAND OAKS, Calif., Sept. 24, 2021 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha® (evolocumab) as an adjunct to diet and other…
Drugs.com – New Drug Approvals

Read More:  Heart healthy diet for heart attack patients